Pharmather Inc (CSE: PHRM) has appointed a prolific Parkinson’s researcher to its team of scientific and clinical advisors. The company this morning announced the appointment of Dr Alberto J Espay to the role, whom currently serves as professor and endowed chair of the University of Cincinnati James A. and Joan A. Gardner Family Center for Parkinson’s Disease and Movement Disorders.
Espay is trained in the field of neurology as well as clinical and electrophysiology of movement disorders, obtaining his education at Indiana University as well as the University of Toronto. He currently also holds a masters degree in clinical epidemiology and healthcare research.
He is currently well regarded in the field of movement disorders and Parkinson’s disease, and currently serves as chair of the MDS Technology Task Force and as secretary of of the Pan American Section of the International Parkinson and Movement Disorder Society. Espay’s research in particular is focused on the measurement of motor and behavioural phenomena in Parkinson’s disease.
“We would like to welcome Dr. Espay as a scientific and clinical advisor to our team and we look forward to his contributions in our clinical development of ketamine in the treatment of levodopa-induced dyskinesia associated with Parkinson’s Disease. Dr. Espay brings invaluable knowledge and experience in the clinical paradigm in Parkinson’s Disease and he will be instrumental in our regulatory and clinical plans to advance our ketamine program for Parkinson’s Disease and movement disorders.”
Fabio Chianelli, CEO of Pharmather
Pharmather is currently working on the clinical development of the use of ketamine in the treatment of levodopa-induced dyskinesia associated with that of Parkinson’s Disease. Espay’s insights and knowledge on the disease is as a result expected to contribute greatly to the advancement of this research.
Pharmather Inc last traded at $0.10 on the CSE.
FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
